Meeting
2018 ASCO Annual Meeting
Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.
Authors
Pedro Nazareth Aguiar
Faculdade de Medicina do ABC, Santo Andre, Brazil
Pedro Nazareth Aguiar , Pui San Tan , Sarah Simko , CARMELIA MARIA NOIA Barreto , Barbara Gutierres Aguiar , Auro Del Giglio , Gilberto Lopes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6615)
DOI
10.1200/JCO.2018.36.15_suppl.6615
Abstract #
6615
Poster Bd #
440
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Daniel Joseph Khalaf
Poster
2021 ASCO Annual Meeting
Survival of veterans treated with enzalutamide and abiraterone in advanced prostate cancer.
First Author: Martin W. Schoen
Poster
2021 ASCO Annual Meeting
Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.
First Author: Larissa Mendes
Poster
2020 Genitourinary Cancers Symposium
The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.
First Author: Yuki Yoshikawa